• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merrimack Pharmaceuticals, Inc. - Common Stock (NQ:MACK)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 15.15 (8)
Ask (Size) 15.16 (1)
Prev. Close 15.13
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 14,400,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q1 2024 ↗
May 16, 2024
Merrimack Pharmaceuticals just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock
May 10, 2024
From Merrimack Pharmaceuticals, Inc.
Via Business Wire

Performance

More News

Read More
News headline image
Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution
May 09, 2024
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
News headline image
Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution
April 30, 2024
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
News headline image
Merrimack Receives $225 Million Milestone Payment from Ipsen
March 27, 2024
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) Highlighted for Surprising Price Action
March 25, 2024
Via Investor Brand Network
News headline image
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023 ↗
March 08, 2024
Via InvestorPlace
News headline image
Merrimack Reports Full Year 2023 Financial Results
March 07, 2024
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
News headline image
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
February 13, 2024
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
News headline image
$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying ↗
December 12, 2023
Via Benzinga
News headline image
Merrimack Reports Third Quarter 2023 Financial Results
November 02, 2023
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Pancreatic Cancer Battle Boosted by $200M VC Firm
September 19, 2023
Via FinancialNewsMedia
Topics Death
News headline image
Merrimack Reports Second Quarter 2023 Financial Results
August 03, 2023
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
News headline image
Merrimack Reports First Quarter 2023 Financial Results
May 04, 2023
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket ↗
March 15, 2023
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
March 15, 2023
Via InvestorPlace
News headline image
Luna Innovations, Guess? And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
March 15, 2023
Via Benzinga
News headline image
Merrimack Reports Full Year 2022 Financial Results
March 09, 2023
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Stocks Insiders Are Buying: Triumph Financial And More ↗
February 01, 2023
Via Benzinga
News headline image
$2.6M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying ↗
January 18, 2023
Via Benzinga
News headline image
Insiders Buying Heska, B. Riley Financial And 2 Other Stocks ↗
January 10, 2023
Via Benzinga
News headline image
$1.4 Million Bet On Joint Corp? Check Out These 3 Stocks Insiders Are Buying ↗
January 04, 2023
Via Benzinga
News headline image
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
December 05, 2022
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
November 15, 2022
Via FinancialNewsMedia
Topics Death
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
November 10, 2022
Via FinancialNewsMedia

Frequently Asked Questions

Is Merrimack Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Merrimack Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Merrimack Pharmaceuticals, Inc. - Common Stock trade on?
Merrimack Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Merrimack Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Merrimack Pharmaceuticals, Inc. - Common Stock is MACK on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap